- Home
- QNTM vs BICO-USD Comparison
QNTM vs BICO-USD Comparison
Compare QNTM & BICO-USD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNTM
- BICO-USD
- Stock Information
- Founded
- QNTM 1998
- BICO-USD N/A
- Country
- QNTM Canada
- BICO-USD
- Employees
- QNTM N/A
- BICO-USD N/A
- Industry
- QNTM
- BICO-USD
- Sector
- QNTM
- BICO-USD
- Exchange
- QNTM NYSE
- BICO-USD
- Market Cap
- QNTM 9.1M
- BICO-USD N/A
- IPO Year
- QNTM N/A
- BICO-USD N/A
- Fundamental
- Price
- QNTM $3.83
- BICO-USD $0.34
- Analyst Decision
- QNTM
- BICO-USD
- Analyst Count
- QNTM 0
- BICO-USD 0
- Target Price
- QNTM N/A
- BICO-USD N/A
- AVG Volume (30 Days)
- QNTM 220.7K
- BICO-USD N/A
- Earning Date
- QNTM 01-14-2025
- BICO-USD N/A
- Dividend Yield
- QNTM N/A
- BICO-USD N/A
- EPS Growth
- QNTM N/A
- BICO-USD N/A
- EPS
- QNTM N/A
- BICO-USD N/A
- Revenue
- QNTM N/A
- BICO-USD N/A
- Revenue This Year
- QNTM N/A
- BICO-USD N/A
- Revenue Next Year
- QNTM N/A
- BICO-USD N/A
- P/E Ratio
- QNTM N/A
- BICO-USD N/A
- Revenue Growth
- QNTM N/A
- BICO-USD N/A
- 52 Week Low
- QNTM $2.70
- BICO-USD N/A
- 52 Week High
- QNTM $70.85
- BICO-USD N/A
- Technical
- Relative Strength Index (RSI)
- QNTM 44.48
- BICO-USD 52.94
- Support Level
- QNTM $3.50
- BICO-USD $0.29
- Resistance Level
- QNTM $4.67
- BICO-USD $0.34
- Average True Range (ATR)
- QNTM 0.67
- BICO-USD 0.03
- MACD
- QNTM 0.05
- BICO-USD 0.00
- Stochastic Oscillator
- QNTM 35.33
- BICO-USD 96.66
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.